CD19 and neoplasm: CAR T cells containing the fully human anti-CD19 IC78 scFv have demonstrated similar properties and in vivo anti-tumor activity compared to the standard anti-CD19 FMC63-containing CAR T cell that has been extensively clinically tested and FDA approved.22